A risk prediction model of linezolid-induced thrombocytopenia for elderly patients with chronic kidney disease is urgently needed

Eur J Hosp Pharm. 2023 Jul;30(4):e21. doi: 10.1136/ejhpharm-2022-003370. Epub 2022 Jun 9.

Authors

Xiaohua Zhou¹, Hongjian Ji²

Affiliations

¹ Department of Nephrology, Yancheng Third People's Hospital, Yancheng, China zhouxiaohua1983@126.com.
² School of Pharmacy, Jiangsu Vocational College of Medicine, Yancheng, China.

PMID: 35680394
PMCID: PMC10359774 (available on 2024-07-01)
DOI: 10.1136/ejhpharm-2022-003370

No abstract available

Keywords: CLINICAL MEDICINE; Kidney Failure, Chronic; Medical Informatics; PHARMACY ADMINISTRATION; PHARMACY SERVICE, HOSPITAL.

Publication types

Letter

MeSH terms

Aged
Anti-Bacterial Agents / adverse effects
Humans
Linezolid / adverse effects
Renal Insufficiency, Chronic* / diagnosis
Renal Insufficiency, Chronic* / epidemiology
Thrombocytopenia* / chemically induced
Thrombocytopenia* / diagnosis

Substances

Linezolid
Anti-Bacterial Agents